Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seres Therapeutics, Inc.    MCRB

SERES THERAPEUTICS, INC.

(MCRB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
24.48(c) 24.96(c) 25.4(c) 24.17(c) 24.05(c) Last
1 265 058 1 423 363 1 389 863 1 488 238 817 811 Volume
-8.35% +1.96% +1.76% -4.84% -0.50% Change
More quotes
Financials (USD)
Sales 2020 22,6 M - -
Net income 2020 -95,7 M - -
Net cash position 2020 260 M - -
P/E ratio 2020 -21,8x
Yield 2020 -
Sales 2021 22,9 M - -
Net income 2021 -123 M - -
Net cash position 2021 92,7 M - -
P/E ratio 2021 -17,3x
Yield 2021 -
Capitalization 2 195 M 2 195 M -
EV / Sales 2020 85,6x
EV / Sales 2021 91,8x
Nbr of Employees 108
Free-Float 90,7%
More Financials
Company
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics... 
More about the company
Notations Surperformance© of Seres Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SERES THERAPEUTICS, INC.
01/19SERES THERAPEUTICS : to Present SER-109 Phase 3 Mechanistic Data at Keystone Sym..
BU
01/11SERES THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Ex..
AQ
01/06SERES THERAPEUTICS : Publishes Positive Data on Phase 1b Ulcerative Colitis Stud..
MT
01/06SERES THERAPEUTICS : to Present at 39th Annual J.P. Morgan Healthcare Conference
BU
01/06SERES THERAPEUTICS : Publishes Positive SER-287 Phase 1b Ulcerative Colitis Stud..
BU
2020SERES THERAPEUTICS : JMP Securities Starts Seres Therapeutics at Market Perform
MT
2020SERES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Amend..
AQ
2020SERES THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Ex..
AQ
2020SERES THERAPEUTICS : to Participate in Upcoming Virtual Investor Conferences
BU
2020Oppenheimer Adjusts Seres Therapeutics PT to $38 From $34, Maintains Outperfo..
MT
2020SERES THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
2020SERES THERAPEUTICS : Corporate Presentation
PU
2020Seres Therapeutics Posts Wider Q3 Net Loss, Revenue Declines
MT
2020SERES THERAPEUTICS : 3Q Earnings Snapshot
AQ
2020Earnings Flash (MCRB) SERES THERAPEUTICS Reports Q3 EPS $-0.36, vs. Street Es..
MT
More news
News in other languages on SERES THERAPEUTICS, INC.
2020NESTLÉ : le titre surnage grâce à un relèvement de broker
More news
Analyst Recommendations on SERES THERAPEUTICS, INC.
More recommendations
Stock Trading Strategies
SERES THERAPEUTICS, INC. - 2020
Close to new upside potential
BUY
More Stock Trading Analysis
Chart SERES THERAPEUTICS, INC.
Duration : Period :
Seres Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SERES THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 37,50 $
Last Close Price 24,05 $
Spread / Highest target 104%
Spread / Average Target 55,9%
Spread / Lowest Target -0,21%
EPS Revisions
Managers and Directors
NameTitle
Eric D. Shaff President, Chief Executive Officer & Director
Stephen A. Berenson Chairman
Marcus Chapman Chief Financial Officer & Senior Vice President
Matthew R. Henn Chief Scientific Officer & Executive VP
Kelly M. Brady Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SERES THERAPEUTICS, INC.-1.84%2 195
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148